198 related articles for article (PubMed ID: 36714951)
1. Ga-68-Edotreotide Positron Emission Tomography/Computed Tomography Somatostatin Receptors Tumor Volume Predicts Outcome in Patients With Primary Gastroenteropancreatic Neuroendocrine Tumors.
Gallicchio R; Giordano A; Milella M; Storto R; Pellegrino T; Nardelli A; Nappi A; Tarricone L; Storto G
Cancer Control; 2023; 30():10732748231152328. PubMed ID: 36714951
[TBL] [Abstract][Full Text] [Related]
2.
Lee H; Eads JR; Pryma DA
Oncologist; 2021 Jan; 26(1):21-29. PubMed ID: 32886441
[TBL] [Abstract][Full Text] [Related]
3. Comparison of gallium-68 somatostatin receptor and
Liu X; Li N; Jiang T; Xu H; Ran Q; Shu Z; Wu J; Li Y; Zhou S; Zhang B
Hell J Nucl Med; 2020; 23(2):188-200. PubMed ID: 32716410
[TBL] [Abstract][Full Text] [Related]
4. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of somatostatin receptor expressing tumor volume calculated from
Toriihara A; Baratto L; Nobashi T; Park S; Hatami N; Davidzon G; Kunz PL; Iagaru A
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2244-2251. PubMed ID: 31350603
[TBL] [Abstract][Full Text] [Related]
6. Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.
Kaemmerer D; Peter L; Lupp A; Schulz S; Sänger J; Prasad V; Kulkarni H; Haugvik SP; Hommann M; Baum RP
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1659-68. PubMed ID: 21626438
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Maximum Standardized Uptake Value in 68Ga-Somatostatin Receptor Positron Emission Tomography for Neuroendocrine Tumors: A Systematic Review and Meta-analysis.
Lee DY; Kim YI
Clin Nucl Med; 2019 Oct; 44(10):777-783. PubMed ID: 31283601
[TBL] [Abstract][Full Text] [Related]
8. Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.
Yu J; Cao F; Zhao X; Xie Q; Lu M; Li J; Yang Z; Sun Y
Neuroendocrinology; 2022; 112(4):358-369. PubMed ID: 34077939
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of atypical
Gossili F; Almasi CE; Zacho HD
Hell J Nucl Med; 2023; 26(2):94-98. PubMed ID: 37527044
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
11. Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach.
Werner RA; Weich A; Higuchi T; Schmid JS; Schirbel A; Lassmann M; Wild V; Rudelius M; Kudlich T; Herrmann K; Scheurlen M; Buck AK; Kropf S; Wester HJ; Lapa C
Theranostics; 2017; 7(6):1489-1498. PubMed ID: 28529632
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic utility of Gallium-68-somatostatin receptor PET/CT in ectopic ACTH-secreting tumors: a systematic literature review and single-center clinical experience.
Varlamov E; Hinojosa-Amaya JM; Stack M; Fleseriu M
Pituitary; 2019 Oct; 22(5):445-455. PubMed ID: 31236798
[TBL] [Abstract][Full Text] [Related]
13. Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study.
Rufini V; Lorusso M; Inzani F; Pasciuto T; Triumbari EKA; Grillo LR; Locco F; Margaritora S; Pescarmona E; Rindi G
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4182-4193. PubMed ID: 35674739
[TBL] [Abstract][Full Text] [Related]
14. Clinical value of
Ma H; Kan Y; Yang JG
Acta Radiol; 2021 Sep; 62(9):1217-1228. PubMed ID: 32985224
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of
Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Whole-Body PET Volumetric Parameters Extracted from
Thuillier P; Liberini V; Grimaldi S; Rampado O; Gallio E; Santi B; Arvat E; Piovesan A; Filippi R; Abgral R; Molinari F; Deandreis D
J Nucl Med; 2022 Jul; 63(7):1014-1020. PubMed ID: 34740949
[TBL] [Abstract][Full Text] [Related]
17. Gallium-68-dotatate PET/CT is better than CT in the management of somatostatin expressing tumors: First experience in Africa.
Lawal IO; Ololade KO; Lengana T; Reyneke F; Ankrah AO; Ebenhan T; Vorster M; Sathekge MM
Hell J Nucl Med; 2017; 20(2):128-133. PubMed ID: 28697189
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of SSTR2 Expression Assessed by
Fonti R; Panico M; Pellegrino S; Pulcrano A; Vastarella LA; Torbati AHM; Giuliano M; Palmieri G; De Placido S; Del Vecchio S
J Nucl Med; 2022 Oct; 63(10):1509-1514. PubMed ID: 35273092
[TBL] [Abstract][Full Text] [Related]
19. Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from
Weber M; Kessler L; Schaarschmidt B; Fendler WP; Lahner H; Antoch G; Umutlu L; Herrmann K; Rischpler C
BMC Cancer; 2020 Apr; 20(1):326. PubMed ID: 32299391
[TBL] [Abstract][Full Text] [Related]
20. Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours.
Virgolini I; Gabriel M; Kroiss A; von Guggenberg E; Prommegger R; Warwitz B; Nilica B; Roig LG; Rodrigues M; Uprimny C
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2072-83. PubMed ID: 27174220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]